Cargando…

Efficacy of Direct-Acting Antivirals in Patients with Hepatitis C Virus/Human Immunodeficiency Virus Coinfection: A Gap between Clinical Trial and Real Practice

Detalles Bibliográficos
Autor principal:	Kim, Do Young
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Editorial Office of Gut and Liver 2018
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254617/ https://www.ncbi.nlm.nih.gov/pubmed/30466200 http://dx.doi.org/10.5009/gnl18418

Ejemplares similares

All‐oral direct‐acting antiviral therapy against hepatitis C virus (HCV) in human immunodeficiency virus/HCV–coinfected subjects in real‐world practice: Madrid coinfection registry findings
por: Berenguer, Juan, et al.
Publicado: (2018)

Liver Cirrhosis as a Risk Factor for Direct-Acting Antiviral Therapy Failure in Real-Life Hepatitis C Virus/Human Immunodeficiency Virus Coinfection
por: Boesecke, Christoph, et al.
Publicado: (2017)

Real-World Clinical Efficacy and Tolerability of Direct-Acting Antivirals in Hepatitis C Monoinfection Compared to Hepatitis C/Human Immunodeficiency Virus Coinfection in a Community Care Setting
por: Gayam, Vijay, et al.
Publicado: (2018)

Antiretroviral Use in the CEASE Cohort Study and Implications for Direct-Acting Antiviral Therapy in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection
por: Martinello, Marianne, et al.
Publicado: (2016)

Multitarget Direct‐Acting Antiviral Therapy Is Associated With Superior Immunologic Recovery in Patients Coinfected With Human Immunodeficiency Virus and Hepatitis C Virus
por: Shrivastava, Shikha, et al.
Publicado: (2018)

Effectiveness of Direct-Acting Antiviral Therapy in Patients With Human Immunodeficiency Virus–Hepatitis C Virus Coinfection in Routine Clinical Care: A Multicenter Study
por: Kim, H Nina, et al.
Publicado: (2019)

Direct-acting antiviral agents against hepatitis C virus and lipid metabolism
por: Kanda, Tatsuo, et al.
Publicado: (2017)

Real-world effectiveness of direct-acting antivirals in people living with human immunodeficiency virus and hepatitis C virus genotype 6 infections
por: Sun, Hsin-Yun, et al.
Publicado: (2022)

Effectiveness of direct-acting antivirals for hepatitis C virus infection in hepatitis C/HIV coinfected individuals: A multicenter study
por: Machado, Soraia M., et al.
Publicado: (2020)

Coinfection of Hepatitis B and Hepatitis C Virus in Patients With Human Immunodeficiency Virus
por: Masroor, Hassan, et al.
Publicado: (2021)

Hepatitis C Virus (HCV) Clearance After Treatment With Direct-Acting Antivirals in Human Immunodeficiency Virus (HIV)-HCV Coinfection Modulates Systemic Immune Activation and HIV Transcription on Antiretroviral Therapy
por: Ghiglione, Yanina, et al.
Publicado: (2020)

Is direct-acting antiviral treatment beneficial or harmful for patients with hepatitis C virus-related hepatocellular carcinoma?
por: Lee, Hye Won
Publicado: (2022)

Real-world efficacy and safety of pangenotypic direct-acting antivirals against hepatitis C virus infection in Taiwan
por: Chang, Kao-Chi, et al.
Publicado: (2021)

Direct-Acting Antivirals in the Treatment of Hepatitis C Virus (HCV)/Human Immunodeficiency Virus (HIV) Co-infected Patients: Real-Life Experience From Nepal
por: KC, Sudhamshu, et al.
Publicado: (2021)

Current treatment for hepatitis C virus/human immunodeficiency virus coinfection in adults
por: Laiwatthanapaisan, Ratchapong, et al.
Publicado: (2021)

Facilitating Patient-Centered Decision Making Around the Timing of Direct-Acting Antivirals in Patients With Hepatitis C Virus and CKD
por: Roche, Meaghan, et al.
Publicado: (2019)

Predictors of Hepatitis C Treatment Failure After Using Direct-Acting Antivirals in People Living With Human Immunodeficiency Virus
por: Cachay, Edward R, et al.
Publicado: (2019)

Human Immunodeficiency Virus/Hepatitis C Virus Coinfection in Spain: Prevalence and Patient Characteristics
por: Berenguer, Juan, et al.
Publicado: (2016)

Direct-Acting Antiviral Treatment Failure Among Hepatitis C and HIV–Coinfected Patients in Clinical Care
por: Rossi, Carmine, et al.
Publicado: (2019)

Do we know enough about human immunodeficiency virus and COVID-19 coinfection?
por: Alabbadi, Ali M., et al.
Publicado: (2020)

The Prevalence and Impact of Hepatic Steatosis on Response to Direct-Acting Antiviral Therapy in HIV–HCV Coinfection
por: Johnson, Leigh P., et al.
Publicado: (2020)

The efficacy and safety of direct-acting antiviral drugs in the management of hepatitis C virus-related arthritis
por: Alian, Samah M., et al.
Publicado: (2020)

Safety and efficacy of directly‐acting antiviral therapy for chronic hepatitis C virus in elderly people
por: De Santis, Adriano, et al.
Publicado: (2021)

Real-world effectiveness and safety of direct-acting antivirals in hepatitis C virus patients with mental disorders
por: Dybowska, Dorota, et al.
Publicado: (2023)

Concomitant Treatment of Hepatitis C Virus and Diffuse Large B-Cell Lymphoma with Direct-Acting Antivirals in HIV Coinfection: A Case Report
por: Gallipani, Alyssa, et al.
Publicado: (2019)

Hepatitis C virus infection in children in the era of direct-acting antiviral
por: Pawlowska, Malgorzata, et al.
Publicado: (2018)

Direct-acting antiviral resistance of Hepatitis C virus is promoted by epistasis
por: Zhang, Hang, et al.
Publicado: (2023)

Insights Into the Coinfections of Human Immunodeficiency Virus-Hepatitis B Virus, Human Immunodeficiency Virus-Hepatitis C Virus, and Hepatitis B Virus-Hepatitis C Virus: Prevalence, Risk Factors, Pathogenesis, Diagnosis, and Treatment
por: Shahriar, Sagarika, et al.
Publicado: (2022)

Selected biochemical and hematological abnormalities in Nigerians with human immunodeficiency virus and hepatitis C virus coinfection
por: Obienu, Olive, et al.
Publicado: (2011)

The impact of hepatitis C virus and human immunodeficiency virus coinfection on survival in patients with hepatocellular carcinoma
por: Spartalis, Eleftherios, et al.
Publicado: (2017)

Risk of hepatitis B reactivation in patients treated with direct-acting antivirals for hepatitis C
por: Aggeletopoulou, Ioanna, et al.
Publicado: (2017)

Tuberculosis in Visceral Leishmaniasis-Human Immunodeficiency Virus Coinfection: An Evidence Gap in Improving Patient Outcomes?
por: van Griensven, Johan, et al.
Publicado: (2018)

Challenge to overcome: Nonstructural protein 5A-P32 deletion in direct-acting antiviral-based therapy for hepatitis C virus
por: Sato, Ken, et al.
Publicado: (2018)

Miliary Tuberculosis Coinfection with Human Immunodeficiency Virus
por: Esteve, Erika, et al.
Publicado: (2010)

Efficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus Infection
por: Lin, Ming V., et al.
Publicado: (2016)

Corrigendum: Insights into the coinfections of human immunodeficiency virus-hepatitis B virus, human immunodeficiency virus-hepatitis C virus, and hepatitis B virus-hepatitis C virus: prevalence, risk factors, pathogenesis, diagnosis, and treatment
por: Shahriar, Sagarika, et al.
Publicado: (2023)

Barriers and Facilitators of Hepatitis C Care in Persons Coinfected with Human Immunodeficiency Virus
por: Bar, Nir, et al.
Publicado: (2022)

Impact of Hepatitis C Virus Cure on Depressive Symptoms in the Human Immunodeficiency Virus-Hepatitis C Virus Coinfected Population in Canada
por: Marathe, Gayatri, et al.
Publicado: (2022)

The Impact of Direct-Acting Antivirals in the Hepatitis C-Sustained Viral Response in Human Immunodeficiency Virus-Infected Patients With Ongoing Barriers to Care
por: Cachay, Edward R., et al.
Publicado: (2015)

Direct-acting Antivirals and Host-targeting Agents against the Hepatitis A Virus
por: Kanda, Tatsuo, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_t9o7kgjf5ka7k3uejcl2r1gi8c